A Two Period, One-sequence Open-label Study of a Newly Developed Calcium Carbonate-vitamin D3 Chewable Tablet Formulation (Calcium 500 mg and Vitamin D3 800) Dosed for Three Days to Investigate the Effect on Urine Calcium and Serum Parathyroid Hormone (PTH) as Measurements of Intestinal Calcium Absorption in Healthy Postmenopausal Women and Healthy Men Compared to Baseline.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Calcium/colecalciferol (Primary)
- Indications Osteoporosis
- Focus Pharmacodynamics
- Acronyms Osteopro
Most Recent Events
- 18 Oct 2013 Biomarkers information updated
- 21 Aug 2012 Actual end date (Aug 2012) added as reported by ClinicalTrials.gov.
- 01 Aug 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.